Predictors of short- and mid-term recurrence of atrial fibrillation after surgical radiofrequency ablation: A six-month transtelephonic electrocardiogram monitoring study

Background: Occurrence of symptomatic, paroxysmal or persistent atrial fibrillation (AF) prior to admission to hospital for the purposes of cardiac surgery constitutes an indication forconsideration of simultaneous surgical radiofrequency (RF) ablation of such tachyarrhythmia. The aim of this study was to evaluate the efficacy of surgical RF ablation in the treatment of AF with the application of ECG teletransmission in monitoring patients during a 6-month follow-up period. Furthermore, clinical and echocardiographic risk factors for arrhythmia recurrences were subject to analysis. As per authors’ knowledge and literature review, so far no papers devoted to the assessment of efficacy of surgical RF ablation with the use of systematic ECG teletransmission have been published.Methods: The study enrolled 61 patients (20 females) suffering from AF who underwent cardiac surgeries and were additionally subject to surgical RF ablation. The mean age of the subjects was 64 ± 9 years. Efficacy of the procedure was monitored with the application of a system enabling transtelephonic transmission of ECG signal. The study cohort was monitored in the period of 6 months. 2198 ECG recordings were obtained for analysis.Results: In the post-hospital follow-up period, no recurrences of AF were observed in the case of 40 (65%) subjects. Post-hospital failure of the surgical RF ablation procedure was associated with an early episode of AF during hospitalization (p = 0.0012), application of monopolar electrode (p = 0.0325) as well as with the surgical procedure performed to treat mitral stenosis (p = 0.0268).Conclusions: Moreover, it was observed that the group of patients without arrhythmia recurrence in the follow-up period was more frequently administered with antiarrhythmic medications (p = 0.0409) and statin (p = 0.0453) prior to the ablation procedure, with statin being more often applied after the procedure (tendency, p = 0.0747). As opposed to ablation in one atrium, biatrial ablation did not result in fewer late arrhythmia recurrences

Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and Working Group on Cardiac Surgery of the Polish Cardiac Society

The Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and the Working Group on CardiacSurgery of the Polish Cardiac Society have released a position statement on risk factors, diagnosis, and management of patients with cancer and valvular heart disease (VHD). VHD can occur in patients with cancer in several ways, for example, it can exist or be diagnosed before cancer treatment, after cancer treatment, be an incidental finding during imaging tests, endocarditis related to immunosuppression, prolonged intravenous catheter use, or combination treatment, and nonbacterial thrombotic endocarditis. It is recommended to employ close cardiac surveillance for patients at high risk of complications during and after cancer treatment and for cancer treatments that may be cardiotoxic to be discussed by a multidisciplinary team. Patients with cancer and pre-existing severe VHD should be managed according to the 2021 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines for VHD management, taking into consideration cancer prognosis and patient preferences